My Portfolio
+
LINK YOUR PORTFOLIO

Ovid Therapeutics Inc OVID:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:08 PM EDT
2.38quote price arrow down-0.01 (-0.42%)
Volume
4,428
Close
2.39quote price arrow down-0.01 (-0.42%)
Volume
2,190,766
52 week range
0.27 - 3.11
Loading...
  • Open2.41
  • Day High2.47
  • Day Low2.32
  • Prev Close2.40
  • 52 Week High3.11
  • 52 Week High Date04/09/26
  • 52 Week Low0.27
  • 52 Week Low Date06/13/25

Latest On Ovid Therapeutics Inc

Key Stats

  • Market Cap446.07M
  • Shares Out186.64M
  • 10 Day Average Volume1.35M
  • Dividend-
  • Dividend Yield-
  • Beta0.19

Latest On Ovid Therapeutics Inc

KEY STATS

  • Open2.41
  • Day High2.47
  • Day Low2.32
  • Prev Close2.40
  • 52 Week High3.11
  • 52 Week High Date04/09/26
  • 52 Week Low0.27
  • 52 Week Low Date06/13/25
  • Market Cap446.07M
  • Shares Out186.64M
  • 10 Day Average Volume1.35M
  • Dividend-
  • Dividend Yield-
  • Beta0.19

RATIOS/PROFITABILITY

  • EPS (TTM)-0.24
  • P/E (TTM)-9.82
  • Fwd P/E (NTM)-5.10
  • EBITDA (TTM)-47.54M
  • ROE (TTM)-18.77%
  • Revenue (TTM)7.122M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-339.33%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/11/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for...
Jeremy Levin Ph.D.
Executive Chairman of the Board
Margaret Alexander
President, Chief Executive Officer, Director
Jeffrey Rona
Chief Business and Financial Officer
Address
441 NINTH AVENUE, 14TH FLOOR
New York, NY
10001
United States